Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype that lacks effective targeted therapies. The epithelial-to-mesenchymal transition (EMT) is a key contributor in the metastatic process. We previously showed the pan-deacetylase inhibitor LBH589 induces CDH1 expression in TNBC cells, suggesting regulation of EMT. The purpose of this study was to examine the effects of LBH589 on the metastatic qualities of TNBC cells and the role of EMT in this process. A panel of breast cancer cell lines (MCF-7, MDA-MB-231, and BT-549), drugged with LBH589, was examined for changes in cell morphology, migration, and invasion in vitro. The effect on in vivo metastasis was examined using immunofluorescent staining of lung sections. EMT gene expression profiling was used to determine LBH589-induced changes in TNBC cells. ZEB overexpression studies were conducted to validate requirement of ZEB in LBH589-mediated proliferation and tumorigenesis. Our results indicate a reversal of EMT by LBH589 as demonstrated by altered morphology and altered gene expression in TNBC. LBH589 was shown to be a more potent inhibitor of EMT than other HDAC inhibitors, SAHA and TMP269. Additionally, we found that LBH589 inhibits metastasis of MDA-MB-231 cells in vivo. These effects of LBH589 were mediated in part by inhibition of ZEB, as overexpression of ZEB1 or ZEB2 mitigated the effects of LBH589 on MDA-MB-231 EMT-associated gene expression, migration, invasion, CDH1 expression, and tumorigenesis. These data indicate therapeutic potential of LBH589 in targeting EMT and metastasis of TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Breast cancer metastasis: markers and models
Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1670 · Cited by 2,232 · cited 1×
“Previously, development of many new therapies was centered on targeting the primary tumor; however, the majority of breast cancer deaths are due to distant metastasis [41].”
BackgroundKokkinos, M. I., Wafai, R., Wong, M. K., Newgreen, D. F., Thompson, E. W., & Waltham, M. (2007) · Cells Tissues Organs · doi:10.1159/000101320 · Cited by 394
Cited by
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types
Lehmann, W., Mossmann, D., Kleemann, J., Mock, K., Meisinger, C., Brummer, T., Herr, R., Brabletz, S., Stemmler, M. P., & Brabletz, T. (2016) · Nature Communications · doi:10.1038/ncomms10498 · Cited by 305
Guestini, F., McNamara, K. M., Ishida, T., & Sasano, H. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1125469 · Cited by 58
“In other in vitro and in vivo studies, the HDACis were also reported to inhibit TNBC primary tumorigenesis and epithelial-mesenchymal transition (EMT) with either a downregulation of RAD52 [33] or the inhibition of zinc-finger E-box-binding (ZEB) [34].”
BackgroundLaser direct-write onto live tissues: a novel model for studying cancer cell migration
Burks, H. E., Phamduy, T. B., Azimi, M. S., Saksena, J., Burow, M. E., Collins‐Burow, B. M., Chrisey, D. B., & Murfee, W. L. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25363 · Cited by 48
“…kinase signaling, chemokine and cytokine receptor active ion, and histone deacetylase (hDAC) inhibitors suppress cancer cell invasion/migration in two-dimensional trans-well assays, which are further supported by regulation of cancer cell metastasis in vivo (Rhodes et al., 2011, 2014, 2015).”
BackgroundSelf-citationKong, Y., Ren, W., Fang, H., Shah, N. A., Shi, Y., You, D., Zhou, C., Jiang, D., Yang, C., Liang, H., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.65322 · Cited by 25
“KLF5 is highly expressed in basal-like breast cancers, including HCC1937 and HCC1806 cell lines, in contrast, KLF5 is lowly expressed in MDA-MB-231 cell line [20].”
Background
Metadata
- Authors
- Rhodes, L. V., Tate, C. R., Segar, H. C., Burks, H. E., Phamduy, T. B., Hoang, V., Elliott, S., Gilliam, D., Pounder, F. N., Anbalagan, M., Chrisey, D. B., Rowan, B. G., Burow, M. E., & Collins-Burow, B. M.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2014-05-09
- Volume
- 145
- Issue
- 3
- Pages
- 593-604
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W1989854110
- Cited by
- 101
- References
- 3
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.